Effect of tamoxifen citrate on a murine renal cell adenocarcinoma.
High-dose tamoxifen citrate (80 mg/kg), or estradiol (100 micrograms/kg) was administered to intact or castrated Balb/C male and female mice with implanted murine renal cell adenocarcinoma. 100% tumor growth occurred, and tumor weights in tamoxifen treated (mean 3.69 g) and untreated (mean 3.11 g) groups were relatively the same. All estradiol-treated groups had slightly lower tumor weights (mean 2.31 g). This was, however, not statistically significant. Metastases occurred in all groups: control groups had 24-50%, tamoxifen-treated groups had 22-61%, and the estradiol-treated groups had 30-75%. In this murine renal adenocarcinoma model, tamoxifen did not appear to retard tumor growth or metastatic spread.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D002369:Castration; D004958:Estradiol / Q000627:therapeutic use; D005260:Female; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011379:Prognosis; D013629:Tamoxifen / Q000627:therapeutic use*
D013629:Tamoxifen; D004958:Estradiol